SCHEMBL22246501

SCHEMBL22246501

N#Cc1cccc(-c2nc3[nH]ccc(=O)c3cc2-c2cc(Cl)c3c(c2)C(=O)NC3=O)c1

nearest known ligand 0.67

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 10/20 0.67
▸ ADORA1 P30542 3/20 0.39
▸ STK10 O94804 2/20 0.38
▸ SLK Q9H2G2 2/20 0.38
▸ CHEK1 O14757 2/20 0.36
▸ WEE1 P30291 1/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ XDH P47989 1/20 0.35
▸ ADORA2B P29275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22250334 0.87 ADORA2A (0.50) ADORA2AADORA1STK10SLKCHEK1
SCHEMBL22246222 0.85 ADORA2A (0.64) ADORA2AADORA1BRD4XDH
SCHEMBL22246503 0.82 ADORA2A (0.44) ADORA2AADORA1STK10SLKCHEK1
SCHEMBL22246451 0.81 ADORA2A (0.74) ADORA2AADORA1BRD4XDH
SCHEMBL22246480 0.81 ADORA2A (0.74) ADORA2AADORA1BRD4XDH
SCHEMBL22246293 0.81 ADORA2A (0.74) ADORA2AADORA1
SCHEMBL22246357 0.81 ADORA2A (0.66) ADORA2AADORA1BRD4XDH
SCHEMBL22230230 0.80 ADORA2A (1.00) ADORA2AADORA1BRD4XDHADORA2B
SCHEMBL22246124 0.80 ADORA2A (0.77) ADORA2AADORA1BRD4XDH
SCHEMBL22246345 0.79 ADORA2A (0.64) ADORA2AADORA1BRD4XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169648-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2022-06-02 — — US disclosed
US-11254670-B2 1,8-naphthyridinone compounds and uses thereof NUVATION BIO INC. (US) 2022-02-22 — — US disclosed
WO-2020150676-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NUVATION BIO INC. (US) 2020-07-23 — — WO disclosed
US-20200231589-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2020-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254670-B2 1,8-naphthyridinone compounds and uses thereof NME1, ADORA2A, GPR68 ADORA2A 2/4885ADORA1 9/4885STK10 1137/4885
US-20200231589-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NME1, ADORA2A, GPR68 ADORA2A 2/4885ADORA1 9/4885STK10 1137/4885
US-20220169648-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NME1, ADORA2A, GPR68 ADORA2A 2/4885ADORA1 9/4885STK10 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback